Search for a trial

Lung cancer Early Molecular Assessment trial

Primary Objective:- To determine the percentage of patients with EGFR mutation, ALK translocation and other genetic aberrations with an improved efficacy of molecular profiling in all stages of NSCLC.- To determine PD-L1 tumour proportion score in…

Phase I Study: safety and immunogenicity of vaccination with XAGE1B long peptides combined with
poly-ICLC in patients with pulmonary adenocarcinoma

Primary objective:* To evaluate the safety of vaccination with XAGE1B peptides emulsified in Montanide ISA 51 co-mixed with the adjuvant Hiltonol® (Poly-ICLC) in patients with pulmonary adenocarcinoma.Secondary objective* To evaluate the capacity of…

A Phase I, Open-label, Non-randomised Study to Assess the Effect of
Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of a Single Oral
Dose of AZD9291 in Patients with EGFRm Positive NSCLC Whose Disease
has Progressed on an EGFR TKI

To investigate the effect of a CYP3A4 inhibitor (itraconazole) on the PK of AZD9291.

Fluid phase biopsy (circulating tumour DNA and serum tumour markers) in
patients with non-small cell lung cancer.

In advanced NSCLC & in first stage of study in locally advanced NSCLC:To assess the kinetics of STMs and ctDNA in plasma before, during and after treatment for NSCLC.Second stage of study in locally advanced NSCLC:To determine the prognostic…

NL NVALT2017 / Translational research for immune modulating and targeted therapy in non-small cell lung cancer, an exploratory NVALT study

* To explore baseline predictive biomarkers for tumor response to immune modulating and targeted treatment in patients with NSCLC.* To develop biomarkers of therapy resistance to anti-PD-1 treatment in patients with NSCLC.* To explore patterns of…

CA209-759: Blood-borne biomarkers for tumor response to Nivolumab in KRAS-mutated non-small cell lung cancer, an exploratory study

Predictive value of patient specific KRAS mutation in ctDNA in serial blood samples (trajectories) and a durable clinical response to nivolumab.

CA209-762: Pilot study of fine needle aspiration (EUS/EBUS) versus histology for PD-L1 staining in lung cancer, a pilot study.

The primary objective for this study is to explore the options for a minimally invasive predictive test for selecting patients for the treatment with an anti-PD1/PD-L1 treatment. The secondary objective is to explore for which patients with PD-L1…

Companion biomarker development for MEDI4736 treated non-small-cell lung cancer patients using 89Zirconium-labeled MEDI4736 * a feasibility study

To assess the safety and biodistribution of 89Zr-MEDI4736 and its uptake in tumor and target irAE tissues.

Phase I/II study with lapatinib plus trametinib in patients with metastatic
KRAS mutant non-small cell lung cancer

Primary objectives Phase I: To determine the recommended phase 2 dose (RP2D) of the lapatinib-trametinib combination in patients with KRASm NSCLC Phase II: To determine the progression free survival of the lapatinib-trametinib combination compared…

Treating metastatic lung cancer. What are patients* and physicians* goals and are they achieved?

To examine the goals of patients and doctors for treatment with chemotherapy, immunotherapy or targeted therapy in metastatic lung cancer and whether these goals are achieved according to patients, doctors and relatives.

89Zirconium-labeled pembrolizumab as predictive imaging biomarker of response and toxicity in pembrolizumab treated patients with non-small-cell lung cancer - a feasibility study

To assess the safety and biodistribution of 89Zr-pembrolizumab and its uptake in tumor and target irAE tissues

Breathing guidance effectiveness for abdominal and thoracic MR imaging UMC Utrecht

To assess the impact of using breathing instructions while performing motion-compensated MR imaging of lesions in the thorax or abdomen aimed at radiotherapy treatment planning as compared to motion-compensated scans without instructions and free-…

Trial NL87938.000.24

Publication withdrawn by sponsor